Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML-Reference-Cited by-同舟云学术

Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML

Published:2014-01-23 Issue:4 Volume:123 Page:554-561
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Laszlo George S.¹,Gudgeon Chelsea J.¹,Harrington Kimberly H.¹,Dell’Aringa Justine²,Newhall Kathryn J.²,Means Gary D.²,Sinclair Angus M.³,Kischel Roman⁴,Frankel Stanley R.⁵,Walter Roland B.¹⁶⁷

Affiliation:

1. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;

2. Molecular Sciences/Oncology Biomarker, Amgen, Inc., Seattle, WA;

3. Oncology Research, Amgen, Inc., Thousand Oaks, CA;

4. ARM BiTE Technology, Amgen Research GmbH, Munich, Germany;

5. Medical Sciences/Early Development, Amgen, Inc., Rockville, MD; and

6. Department of Medicine, Division of Hematology and

7. Department of Epidemiology, University of Washington, Seattle, WA

Abstract

Key Points AMG 330 cytotoxicity against AML cells is proportional to the level of CD33 expression but is not affected by ABC transporter activity. AMG 330 cytotoxicity is amenable to modulation and augmentation by clinically available drugs such as histone deacetylase or DNA methyltransferase I inhibitors.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/123/4/554/1378236/554.pdf

Reference43 articles.

1. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy.;Walter;Blood,2012

2. Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin.;Cowan;Front Biosci (Landmark Ed),2013

3. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.;Burnett;J Clin Oncol,2011

4. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.;Burnett;J Clin Oncol,2012

5. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.;Castaigne;Lancet,2012

Cited by 152 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the membrane-proximal C2-set domain of CD33 for improved CAR T cell therapy;Molecular Therapy: Oncology;2024-09

2. A novel bispecific T-cell engager using the ligand-target csGRP78 against acute myeloid leukemia;Cellular and Molecular Life Sciences;2024-08-28

3. Multiantigen T-Cell Hybridizers: A Two-Component T-Cell-Activating Therapy;ACS Nano;2024-08-16

4. A dual-targeting approach with anti-IL10R CAR-T cells engineered to release anti-CD33 bispecific antibody in enhancing killing effect on acute myeloid leukemia cells;Cellular Oncology;2024-07-15

5. Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation study;Leukemia & Lymphoma;2024-05-07